Sanctuary Advisors LLC Cuts Stake in Halozyme Therapeutics, Inc. $HALO

Key Points

• Sanctuary Advisors cut its Halozyme stake by 56.2% in the first quarter, selling 16,543 shares and retaining 12,907 shares worth approximately $834,000. Institutional investors still own 97.79% of the company.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $81.60; eight analysts rate the stock Buy, four Hold, and one Sell.
• Halozyme reported quarterly EPS of $1.60, beating estimates of $1.54, while revenue rose 42.2% year over year to $376.71 million. Shares opened at $81.93, near their 52-week high of $82.99, while insiders have sold 74,102 shares over the past 90 days.

Sanctuary Advisors LLC lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 56.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,907 shares of the biopharmaceutical company's stock after selling 16,543 shares during the quarter. Sanctuary Advisors LLC's holdings in Halozyme Therapeutics were worth $834,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Larson Financial Group LLC raised its position in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 343 shares during the period. Measured Wealth Private Client Group LLC grew its position in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 124 shares during the period. Harbour Investments Inc. grew its position in shares of Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 372 shares during the period. Clearstead Advisors LLC increased its stake in shares of Halozyme Therapeutics by 64.8% during the 4th quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 331 shares during the last quarter. Finally, Wexford Capital LP purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $70,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HALO. Benchmark reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Weiss Ratings raised Halozyme Therapeutics from a "hold (c)" rating to a "buy (b-)" rating in a report on Tuesday, May 12th. UBS Group reissued a "buy" rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen upgraded Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, May 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $95.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $81.60.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $81.93 on Monday. The firm has a market capitalization of $9.72 billion, a P/E ratio of 29.47, a PEG ratio of 0.34 and a beta of 0.84. Halozyme Therapeutics, Inc. has a one year low of $57.67 and a one year high of $82.99. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The business has a fifty day moving average price of $73.08 and a 200-day moving average price of $70.58.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm's revenue for the quarter was up 42.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,625 shares of the business's stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the transaction, the director owned 42,044 shares of the company's stock, valued at approximately $3,225,195.24. The trade was a 3.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the company's stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $61,245,810.60. This trade represents a 0.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 74,102 shares of company stock valued at $5,205,798. 2.50% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.